Generation of a highly expressing, regulatory acceptable clonal cell line is the first key activity in the development of a biopharmaceutical. Cell line development is labour intensive, time consuming and costly and is subject to stringent regulations to ensure patient safety.
All cell lines used to produce clinical batches of biopharmaceuticals are required to conform to ICH5Q which requires that cell lines are demonstrated to have a traceable history, are clonal and their construction is fully documented.
Dr Jonathan H DempseyJoin DDW and Sphere Fluidics for this exclusive on-demand event Embedding Quality into Cell Line Development Through the Application of an Innovative Picodroplet-Based Single Cell Sorter on 23 November at 3PM GMT.
In this webinar, Dr Jonathan H Dempsey, Managing Director of Dempsey Consulting and Founding Partner of Pathway Biopharma Consulting, describes the implementation of an innovative technology which provides a visual record of clonality, history and clone derivation and also allows for transfected pool enrichment resulting in highly expressing clones.
A comparison of this instrument with existing methods and highlight benefits of traceability and speed from transfection to a clonal cell line is presented.
What you will learn:
- How to improve quality in cell line development
- About the application picodroplet technology for single cell analysis
- How to improve speed and efficiency in cell line development workflows